📰 Dan Budwick News
Page 4 - Dan Budwick News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Dan Budwick. Real-time updates on events, politics, business and more.
February 8, 2024
The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globallySOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 -- Alector, Inc. and GSK plc today...
February 8, 2024
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) and GSK plc (LSE/NYSE: GSK) today announced that the...
February 1, 2024
CAMBRIDGE, Mass., Feb. 01, 2024 -- Prime Medicine, Inc. , a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that...
January 31, 2024
31.01.2024 - WALTHAM, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) - Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced ...
January 19, 2024
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering...
January 17, 2024
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 -- Alector, Inc. , a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an underwritten public offering of...
January 8, 2024
SAN DIEGO, Jan. 07, 2024 -- Singular Genomics Systems, Inc. , a company leveraging novel next-generation sequencing and multiomics technologies to empower researchers and clinicians, today...
January 8, 2024
Dosing XTX301 at 45 ug/kg once every three weeks in ongoing Phase 1 trial, nearly 100x the maximum tolerated dose of rhIL-12, with no dose-limiting toxicities observed to date Initiated patient...
January 8, 2024
Dosing XTX301 at 45 ug/kg once every three weeks (dose level 3) in ongoing Phase 1 trial, nearly 100x the maximum tolerated dose of rhIL-12, with no dose-limiting toxicities observed
January 8, 2024
First Patient Dosed and Successfully Engrafted in BEACON Phase 1/2 Trial of BEAM-101 in Patients with Severe Sickle Cell Disease; Significant Enrollment Progress Supports First Expected Clinical Data...